×
Entrez Id:
2322
Gene Symbol:
FLT3
FLT3
0.520
Biomarker
disease
CTD_human
Dynamics of clonal evolution in myelodysplastic syndromes.
27992414
2017
×
Entrez Id:
2322
Gene Symbol:
FLT3
FLT3
0.520
GeneticVariation
disease
BEFREE
Trisomy 8 alone was associated with older age (median age 10.1 years), FAB M2 (33%), and FLT3 -ITD mutations (58%).
27153159
2016
×
Entrez Id:
2322
Gene Symbol:
FLT3
FLT3
0.520
Biomarker
disease
CTD_human
Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.
27099147
2016
×
Entrez Id:
2322
Gene Symbol:
FLT3
FLT3
0.520
Biomarker
disease
CTD_human
Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia.
24526162
2014
×
Entrez Id:
2322
Gene Symbol:
FLT3
FLT3
0.520
Biomarker
disease
CTD_human
BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.
25053825
2014
×
Entrez Id:
2322
Gene Symbol:
FLT3
FLT3
0.520
Biomarker
disease
CTD_human
Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3.
23906301
2013
×
Entrez Id:
2322
Gene Symbol:
FLT3
FLT3
0.520
Biomarker
disease
CTD_human
Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment.
23036488
2013
×
Entrez Id:
2322
Gene Symbol:
FLT3
FLT3
0.520
Biomarker
disease
CTD_human
Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.
22409268
2012
×
Entrez Id:
2322
Gene Symbol:
FLT3
FLT3
0.520
Biomarker
disease
CTD_human
Combined effects of FLT3 and NF-κB selective inhibitors on acute myeloid leukemia in vivo.
21928377
2012
×
Entrez Id:
2322
Gene Symbol:
FLT3
FLT3
0.520
SomaticCausalMutation
disease
ORPHANET
Molecular and clinicopathologic characterization of AML with isolated trisomy 4.
22338050
2012
×
Entrez Id:
2322
Gene Symbol:
FLT3
FLT3
0.520
Biomarker
disease
CTD_human
Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.
21482694
2011
×
Entrez Id:
2322
Gene Symbol:
FLT3
FLT3
0.520
Biomarker
disease
CTD_human
Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice.
21441929
2011
×
Entrez Id:
2322
Gene Symbol:
FLT3
FLT3
0.520
Biomarker
disease
CTD_human
Micro-RNAs and copy number changes: new levels of gene regulation in acute myeloid leukemia.
19822134
2010
×
Entrez Id:
2322
Gene Symbol:
FLT3
FLT3
0.520
GeneticVariation
disease
BEFREE
Prevalence of FLT3 -ITD is as high as 70% among patients with t(6;9) AML, and patients with t(6;9) AML and FLT3 -ITD mutations usually have higher white blood cell counts, higher bone marrow blasts, and significantly lower rates of complete remission. t(6;9) is most commonly associated with AML-FAB-M2 and is considered by some researchers to be a separate disease entity because of its distinct clinical and morphologic features and poor prognostic implication.
18976025
2008
×
Entrez Id:
2322
Gene Symbol:
FLT3
FLT3
0.520
Biomarker
disease
CTD_human
Dual treatment with FLT3 inhibitor SU11657 and doxorubicin increases survival of leukemic mice.
17184839
2007
×
Entrez Id:
2322
Gene Symbol:
FLT3
FLT3
0.520
Biomarker
disease
CTD_human
Synergistic effect of arsenic trioxide and flt3 inhibition on cells with flt3 internal tandem duplication.
17050201
2006